0
0 (0%)
Artelo Biosciences, Inc. [ATLEW]
Source:
Company Overview
Artelo Biosciences, Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.
| Country | United States |
| Headquarters | solana beach, california |
| Phone Number | 858-925-7049 |
| Industry | manufacturing |
| CEO | Gregory D. Gorgas |
| Website | www.artelobio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-10.1 |
| Net Income | $-9.8 |
| Net Cash | $-0.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -110.8% |
| Profit as % of Stockholder Equity | -343.9% |
Management Effectiveness
| Return on Equity | -343.9% |
| Return on Assets | -209.2% |
| Turnover Ratio | |
| EBITA | $-10.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $4.7 |
| Total Liabilities | $1.8 |
| Operating Cash Flow | $-8.4 |
| Investing Cash Flow | $7.8 |
| Financing Cash Flow | $0.1 |
